|
Video: What is a Stock Split?
|
|
Marinus Pharmaceuticals is a pharmaceutical company focused on the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus. The U.S Food and Drug Administration approved the use of ZTALMY (ganaxolone) oral suspension for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder in patients two years of age and older. Co. is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. According to our MRNS split history records, Marinus Pharmaceuticals has had 1 split. | |
|
Marinus Pharmaceuticals (MRNS) has 1 split in our MRNS split history database. The split for MRNS took place on September 23, 2020. This was a 1 for 4 reverse split, meaning for each 4 shares of MRNS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
When a company such as Marinus Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MRNS split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Marinus Pharmaceuticals shares, starting with a $10,000 purchase of MRNS, presented on a split-history-adjusted basis factoring in the complete MRNS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
08/01/2014 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$32.00 |
|
End price/share: |
$1.44 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.50% |
|
Average Annual Total Return: |
-27.28% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$449.70 |
|
Years: |
9.74 |
|
|
|
Date |
Ratio |
09/23/2020 | 1 for 4 |
|
|